Clinical Trial Update: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria [Phase 2]

View source ↗

Summary

A Phase 2 multicenter randomized trial of EP262 for chronic spontaneous urticaria was terminated, and the results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• EP262

Snippet

Sponsor: Escient Pharmaceuticals, Inc | Conditions: Chronic Spontaneous Urticaria | Phase 2 | Status: TERMINATED | Results posted: 2025-12-05